BioSpace News Archive

Many consumers are left trying to balance cost with desired results and unsure which provider to trust.

Applications open today for the Mindset Award for Workplace Mental Health Reporting, offering a prize of $1,000 for excellent Canadian journalism on the subject in English in 2018

With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation

The meeting will be held at the Lotte New York Palace, 455 Madison Avenue at 50th Street, New York, New York.

Medline, a global manufacturer and distributor of medical and laboratory products with patient-centered solutions, services and expertise across the continuum of care, today announced it has been awarded a group purchasing agreement for laboratory distribution services with Intalere, effective January 1, 2019 for two years.

Northwestern Memorial Hospital is the first in the country to successfully complete robotic-assisted lung volume reduction surgery (LVRS) using the da Vinci Xi Surgical System® to remove diseased, emphysematous tissue within the lungs for the treatment of severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD).

MinervaX, a privately held Danish biotech company, announces today that is has been awarded an investment of 3.6 mEUR from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR).

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes

Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019.